The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance

Biomedicine and Pharmacotherapy

Volumn 67, Issue 7, 2013, Pages 669-680

  Januchowski, Radosław ^a   Wojtowicz, Karolina ^a   Zabel, Maciej ^a,b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

ALDH enzymes; Cancer stem cells; Differentiation therapy

Indexed keywords

ALDEHYDE DEHYDROGENASE; AZACITIDINE; BEXAROTENE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENTINOSTAT; ETOPOSIDE; FENRETINIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; ISOTRETINOIN; NAVELBINE; PACLITAXEL; PERFOSFAMIDE; PERIFOSINE; RETINOIC ACID; TAMOXIFEN; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL DIVISION; CELL ISOLATION; CELL RENEWAL; CELL SELECTION; CELL TRANSDIFFERENTIATION; CHONDROSARCOMA; COLORECTAL CANCER; DNA DAMAGE; DRUG BINDING; ENZYME ACTIVITY; ENZYME KINETICS; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MONOTHERAPY; NEOPLASM; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; REVIEW; STOMACH CANCER;

ALDH ENZYMES; CANCER STEM CELLS; DIFFERENTIATION THERAPY;

ALDEHYDE DEHYDROGENASE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; RETINOIDS; SIGNAL TRANSDUCTION;

EID: 84884812845     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.04.005     Document Type: Review

References (180)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Clarke M., Collins R., Darby S., Davies C., Elphinstone P., Evans E., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106.
3. Cole B.F., Gelber R.D., Gelber S., Coates A.S., Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 2001, 358:277-286.
4. Stavrovskaya A.A. Cellular mechanism of multidrug resistance of tumor cells. Biochemistry 2000, 65(1):95-106.
5. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
6. Kruh G.D. Introduction to resistance to anticancer agents. Oncogene 2003, 22(47):7262-7264.
7. Catalano A., Rodilossi S., Rippo M.R., Caprari P., Procopio A. Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. J Biol Chem 2004, 279:46706-46714.
8. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006, 580(12):2903-2909.
9. Leonard G.D., Fojo T., Bates S.E. Te role of ABC transporters in clinical practice. Oncologist 2003, 8(5):411-424.
10. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP dependent transporters. Nat Rev Cancer 2002, 2:48-58.
11. Fletcher J.I., Haber M., Henderson M.J., Norris M.D. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010, 10:147-156.
12. Choi C.H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005, 5:30.
13. Austin Doyle L., Yang W., Abruzzo L.V., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998, 95(26):15665-15670.
14. Robey R.W., Polgar O., Deeken J., To K.W., Bates S.E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007, 26(1):39-57.
15. Maliepaard M., Van Gastelen M.A., De Jong L.A., et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecanselected ovarian tumor cell line. Cancer Res 1999, 59(18):4559-4563.
16. Cole S.P., Bhardwaj G., Gerlach J.H., et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258:1650-1654.
17. Fardel O., Jigorel E., LeVee M., Payen L. Physiological, pharmacological and clinical features of the multidrug resistance protein 2. Biomed Pharmacother 2005, 59:104-114.
18. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984, 44:5156-5160.
19. Sun Q.L., Sha H.F., Yang X.H., Bao G.L., Lu J., Xie Y.Y. Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol. J Cancer Res Clin Oncol 2011, 137:521-532.
20. Tanei T., Morimoto K., Shimazu K., et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009, 15:4234-4241.
21. + human breast cancer cells. Breast Cancer Res Treat 2012, 133(1):75-87.
22. Moitra K., Lou H., Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 2011, 89:491-502.
23. Alison M.R., Lin W.R., Lim S.M.L., Nicholson L.J. Cancer stem cells: in the line of fire. Cancer Treat Rev 2012, 38:589-598.
24. Scharenberg C.W., Harkey M.A., Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002, 99:507-512.
25. Tang L., et al. Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells. BMC Pharmacol 2010, 10:12.
26. Wang X.Q., Ongkeko W.M., Chen L., et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 2010, 52:528-539.
27. Lee T.K., Castilho A., Cheung V.C., et al. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 2011, 53:160-170.
28. Zhang F., Throm S.L., Murley L.L., et al. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochem Pharmacol 2011, 82:24-34.
29. Balabanov S., Gontarewicz A., Keller G., et al. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. PLoS One 2011, 6:e19164.
30. Agarwal S., Hartz A.M., Elmquist W.F., Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des 2011, 17:2793-2802.
31. Chabner B.A., Roberts T.G. Chemotherapy and the war on cancer. Nat Rev Cancer 2005, 5:65-72.
32. Gerlinger M., Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010, 103:1139-1143.
33. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
34. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011, 17:313-319.
35. Shackleton M., Quintana E., Fearon E.R., Morrison S.J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138(5):822-829.
36. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
37. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
38. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
39. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951.
40. Bapat S.A., Mali A.M., Koppikar C.B., Kurrey N.K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005, 65:3025-3029.
41. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15:504-514.
42. Tirino V., Camerlingo R., Franco R., Malanga D., La Rocca A., Viglietto G., et al. The role of CD133 in the identification and characterization of tumor-initiating cells in non-small cell lung cancer. Eur J Cardiothorac Surg 2009, 36:446-453.
43. Takaishi S., Okumura T., Tu S., Wang S.S., Shibata W., Vigneshwaran R., et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27:1006-1020.
44. Tirino V., Desiderio V., d'Aquino R., De Francesco F., Pirozzi G., Graziano A., et al. Detection and characterization of CD133 cancer stem cells in human solid tumors. PLoS One 2008, 3:e3469.
45. Tirino V., Desiderio V., Paino F., De Rosa A., Papaccio F., Fazioli F., et al. Human primary bone sarcomas contain CD133 cancer stem cells displaying high tumorigenicity in vivo. FASEB J 2011, 25:2022-2030.
46. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
47. Fang D., Nguyen T.K., Leishear K., Finko R., Kulp A.N., Hotz S., et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005, 65:9328-9337.
48. Quintana E., Shackleton M., Sabel M.S., et al. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
49. Mueller M.T., Hermann P.C., Witthauer J., Rubio-Viqueira B., Leicht S.F., Huber S., et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009, 137:1102-1113.
50. Dylla S.J., Beviglia L., Park I.K., Chartier C., Raval J., Ngan L., et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008, 3(6):e2428.
51. + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
52. Levina V., Marrangoni A.M., DeMarco R., Gorelik E., Lokshin A.E. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008, 3(8):e3077.
53. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679.
54. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
55. Scheel C., Weinberg R.A. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells?. Int J Cancer 2011, 129:2310-2314.
56. Floor S., van Staveren W.C., Larsimont D., Dumont J.E., Maenhaut C. Cancer cells in epithelial to mesenchymal transition and tumor-propagating: cancer stem cells: distinct, overlapping or same populations. Oncogene 2011, 30(46):4609-4621.
57. Maheswaran S., Haber D.A. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev 2010, 20:96-99.
58. Szilvassy S.J., Humphries R.K., Lansdorp P.M., et al. Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy. Proc Natl Acad Sci U S A 1990, 87:8736-8740.
59. Clevers H. Stem cells, asymmetric division and cancer. Nat Genet 2005, 37:1027-1028.
60. Graham S.M., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325.
61. Mohrin M., Bourke E., Alexander D., Warr M.R., Barry-Holson K., Le Beau M.M., et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair andmutagenesis. Cell Stem Cell 2010, 7:174-185.
62. Viale A., De Franco F., Orleth A., Cambiaghi V., Giuliani V., Bossi D., et al. Cell cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009, 457:51-56.
63. Hirschmann-Jax C., et al. A distinct "side-population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004, 101:14228-14233.
64. Tirino V., Desiderio V., Paino F., De Rosa A., Papaccio F., La Noce M., et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 2012, 12:218-222.
65. Yu Z., Pestellc T.G., Lisantic M.P., Pestellb R.G. Cancer stem cells. Int J Biochem Cell Biol 2012, 44:2144-2151.
66. Moserle L., Indraccolo S., Ghisi M., Frasson C., Fortunato E., Canevari S., et al. The side-population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res 2008, 68:5658-5668.
67. Rybak A.P., He L., Kapoor A., Cutz J.C., Tang D. Characterization of sphere propagating cells with stem-like properties from DU145 prostate cancer cells. Biochim Biophys Acta 2011, 1813:683-694.
68. Dean M., Fojo T., Bates S. Tumor stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
69. Suva M.L., Riggi N., Stehle J.C., Baumer K., Tercier S., Joseph J.M., et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 2009, 69:1776-1781.
70. Rosen J.M., Jordan C.T. The increasing complexity of the cancer stem cell paradigm. Science 2009, 324:1670-1673.
71. O'Brien C.A., Kreso A., Jamieson C.H. Cancer stem cells and self-renewal. Clin Cancer Res 2010, 16:3113-3120.
72. Ouyang G., Wang Z., Fang X., Liu J., Yang C.J. Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells. Cell Mol Life Sci 2010, 67:2605-2618.
73. Albers A.E., Chen C., Köberle B., Qian X., Klussmann J.P., Wollenberg B., et al. Stem cells in squamous head and neck cancer. Crit Rev Oncol Hemato 2012, 83:224-240.
74. Awad O., Yustein J.T., Shah P., Gul N., Katuri V., O'Neill A., et al. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWSFLI1 inhibition. PLoS One 2010, 5:e13943.
75. Tirino V., Desiderio V., Paino F., Papaccio G., De Rosa M. Methods for cancer stem cell detection and isolation. Methods Mol Biol 2012, 879:513-529.
76. Sladek N.E. Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 2003, 17:7-23.
77. Vasiliou V., Pappa A., Estey T. Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab Rev 2004, 36:279-299.
78. Vasiliou V., Nebert D.W. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics 2005, 2:138-143.
79. Marchitti S.A., Brocker C., Stagos D., Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 2008, 4:697-720.
80. Black W.J., Stagos D., Marchitti S.A., et al. Human aldehyde dehydrogenase genes: alternatively spliced transcriptional transcriptional variants and their suggested nomenclature. Pharmacogen Genomics 2009, 19:893-902.
81. Douville J., Beaulieu R., Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 2009, 18:17-25.
82. Ma I., Allan A.L. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 2011, 7:292-306.
83. Giogianni F., Bridson P.K., Sorrentino B.P., Pohl J., Blakley R.L. Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3. Biochem Pharmacol 2000, 60:325-338.
84. Magni M., Shammah S., Schiro R., Mellado W., Dalla-Favera R., Gianni A.M. Induction of cyclophosphamide resistance by aldehyde dehydrogenase gene transfer. Blood 1996, 87:1097-1103.
85. Moreb J.S., Schweder M., Gray B.A., Zucali J.R., Zori R. In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. Human Gene Therapy 1998, 9:611-619.
86. Kastan M.B., Schlaffer E., Russo J.E., Colvin O.M., Civin C.I., Hilton J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990, 75:1940-1947.
87. Storms R.W., Trujillo A.P., Springer J.B., et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci U S A 1999, 96:9118-9123.
88. Ginestier C., Hur M.H., Charafe-Jauffret E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
89. Chute J.P., Muramoto G.G., Whitesides J., et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A 2006, 103:11707-11712.
90. Corti S., Locatelli F., Papadimitriou D., et al. Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells 2006, 24:975-985.
91. Pearce D.J., Bonnet D. The combined use of Hoechst efflux ability and aldehyde dehydrogenase activity to identify murine and human hematopoietic stem cells. Exp Hematol 2007, 35:1437-1446.
92. Armstrong L., Stojkovic M., Dimmick I., et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004, 22:1142-1151.
93. Jean E., Laoudj-Chenivesse D., Notarnicola C., et al. Aldehyde dehydrogenase activity promotes survival of human muscle precursor cells. J Cell Mol Med 2011, 15(1):119-133.
94. Estes B.T., Wu A.W., Storms R.W., Guilak F. Extended passaging, but not aldehyde dehydrogenase activity, increases the chondrogenic potential of human adipose-derived adult stem cells. J Cell Physiol 2006, 209:987-995.
95. Pearce D.J., Taussig D., Simpson C., et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005, 23:752-760.
96. Ran D., Schubert M., Pietsch L., et al. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol 2009, 37:1423-1434.
97. Cheung A.M., Wan T.S., Leung J.C., et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007, 21:1423-1430.
98. Lingala S., Cui Y.Y., Chen X., et al. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol 2010, 89:27-35.
99. Clay M.R., Tabor M., Owen J.H., et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010, 32(9):1195-1201.
100. Rasheed Z.A., Yang J., Wang Q., et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010, 102(5):340-351.
101. Ucar D., Cogle C.R., Zucali J.R., et al. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009, 178:48-55.
102. van den Hoogen C., van der Horst G., Cheung H., et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010, 70:5163-5173.
103. Su Y., Qiu Q., Zhang X., et al. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 2010, 19:327-337.
104. Deng S., Yang X., Lassus H., et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS ONE 2010, 5:e10277.
105. Lugli A., Iezzi G., Hostettler I., et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010, 103(3):382-390.
106. Li T., Su Y., Mei Y., et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 2010, 90:234-244.
107. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69(4):1302-1313.
108. Park S.Y., Lee H.E., Li H., et al. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010, 16:876-887.
109. Morimoto K., Kim S.J., Tanei T., et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009, 100:1062-1068.
110. Chang B., Liu G., Xue F., et al. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 2009, 22:817-823.
111. Chen Y.C., Chen Y.W., Hsu H.S., et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009, 385:307-313.
112. Jimeno A., Feldmann G., Suarez-Gauthier A., et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009, 8:310-314.
113. Jiang F., Qiu Q., Khanna A., et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7:330-338.
114. Jiang T., Collins B.J., Jin N., et al. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res 2009, 69:845-854.
115. Moreb J.S., Mohuczy D., Ostmark B., et al. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol 2007, 59:127-136.
116. Moreb J.S., Gabr A., Vartikar G.R., et al. Retinoic acid downregulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J Pharmacol Exp Ther 2005, 312:339-345.
117. Dylla S.J., Beviglia L., Park I.K., et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008, 3:e2428.
118. Chu P., Clanton D.J., Snipas T.S., et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 2009, 124:1312-1321.
119. Huang E.H., Hynes M.J., Zhang T., et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009, 69:3382-3389.
120. Honoki K., Fujii H., Kubo A., et al. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 2010, 24:501-505.
121. Theodosiou M., Laudet V., Schubert M. From carrot to clinic: an overview of the retinoic acid signaling pathway. Cell Mol Life Sci 2010, 67:1423-1445.
122. Orfanos C.E., Zouboulis C.C., Almond-Roesler B., Geilen C.C. Current use and future potential role of retinoids in dermatology. Drugs 1997, 53:358-388.
123. Duvic M., Hymes K., Heald P., Breneman D., Martin A.G., Myskowski P., et al. Bexarotene is effective and safe for treatment of refractory advanced stage cutaneous T cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001, 19:2456-2471.
124. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Ogden A., et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997, 337:1021-1028.
125. Bushue N., Wan Y.J. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 2010, 62(13):1285-1298.
126. Duester G., Mic F.A., Molotkov A. Cytosolic retinoid dehydrogenases govern ubiquitous metabolism of retinol to retinaldehyde followed by tissue-specific metabolism to retinoic acid. Chem Biol Interact 2003, 143-4:201-210.
127. Alvarez S., Germain P., Alvarez R., Rodriguez-Barrios F., Gronemeyer H., de Lera A.R. Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor. Int J Biochem Cell Biol 2007, 39:1406-1415.
128. Sporn M., Roberts A., Goodman D. The Retinoids: Biology, Chemistry and Medicine 1994, Raven Press, New York, p.331.
129. Gendimenico G.J., Stim T.B., Corbo M., Janssen B., Mezick J.A. A pleiotropic response is induced in F9 embryonal carcinoma cells and rhino mouse skin by All-trans-retinoic acid, a RAR agonist but not by SR 11237, a RXR-selective agonist. J Invest Dermatol 1994, 102:676-680.
130. Elizondo G., Medina-Diaz I.M., Cruz R., Gonzalez F.J., Vega L. Retinoic acid modulates retinaldehyde dehydrogenase 1 gene expression through the induction of GADD153-C/EBPbeta interaction. Biochem Pharmacol 2009, 77:248-257.
131. Marlétaz F., Holland L.Z., Laudet V., Schubert M. Retinoic acid signaling and the evolution of chordates. Int J Biol Sci 2006, 2:38-47.
132. Ross-Innes C.S., Stark R., Holmes K.A., Schmidt D., Spyrou C., Russell R., et al. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev 2010, 24(2):171-182.
133. Formelli F., Cleris L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 1993, 53:5374-5376.
134. Shalinsky D.R., Bischoff E.D., Gregory M.L., Lamph W.W., Heyman R.A., Hayes J.S., et al. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin Cancer Res 1996, 2:511-520.
135. Grunt T., Dittrich E., Offterdinger M., Schneider S.M., Dittrich C., Huber H. Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Br J Cancer 1998, 78:79-87.
136. Pettersson F., Colston K.W., Dalgleish A.G. Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas 2001, 23:273-279.
137. Kalemkerian G.P., Ou X. Activity of fenretinide plus chemotherapeutic agents in small cell lung cancer cell lines. Cancer Chemother Pharmacol 1999, 43:145-150.
138. Moreb J., Schweder M., Suresh A., Zucali J.R. Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther 1996, 3:24-30.
139. Moreb J.S., Schweder M., Gray B., Zucali J., Zori R. In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. Hum Gene Ther 1998, 9:611-619.
140. Moreb J.S., Baker H.V., Chang L.J., et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer 2008, 7:87.
141. Moreb J.S., Maccow C., Schweder M., Hecomovich J. Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. J Pharmacol Exp Ther 2000, 293:390-396.
142. Luo P., Wang A., Payne K.J., et al. Intrinsic retinoic acid receptor-alpha-cyclin-dependent kinase-activating kinase signaling involves coordination of the restricted proliferation and granulocytic differentiation of human hematopoietic stem cells. Stem Cells 2007, 25:2628-2637.
143. Simandi Z., Balint B.L., Poliska S., Ruhl R., Nagy L. Activation of retinoic acid receptor signaling coordinates lineage commitment of spontaneously differentiating mouse embryonic stem cells in embryoid bodies. FEBS Lett 2010, 584:3123-3130.
144. Su Z.Y., Li Y., Zhao X.L., Zhang M. All-trans retinoic acid promotes smooth muscle cell differentiation of rabbit bone marrow-derived mesenchymal stem cells. J Zhejiang Univ Sci B 2010, 11:489-496.
145. Tonge P.D., Andrews P.W. Retinoic acid directs neuronal differentiation of human pluripotent stem cell lines in a non-cell-autonomous manner. Differentiation 2010, 80:20-30.
146. Petrie K., Zelent A., Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009, 16:84-91.
147. Elizondo G., Corchero J., Sterneck E., Gonzalez F.J. Feedback inhibition of the retinaldehyde dehydrogenase gene ALDH1 by retinoic acid through retinoic acid receptor-alpha and CCAAT/enhancer-binding protein beta. J Biol Chem 2000, 275:39747-39753.
148. Hong W.K., Endicott J., Itri L.M., Doos W., Batsakis J.G., Bell R., et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986, 315:1501-1505.
149. Khuri F.R., Lee J.J., Lippman S.M., Kim E.S., Cooper J.S., Benner S.E., et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006, 98:441-450.
150. Arrieta O., Gonzalez-De la Rosa C.H., Arechaga-Ocampo E., Villanueva-Rodriguez G., Ceron-Lizarraga T.L., Martinez-Barrera L., et al. Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small cell lung cancer. J Clin Oncol 2010, 28:3463-3471.
151. Ramlau R., Zatloukal P., Jassem J., Schwarzenberger P., Orlov S.V., Gottfried M., et al. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer: SPIRIT I. J Clin Oncol 2008, 26:1886-1892.
152. Budd G.T., Adamson P.C., Gupta M., Homayoun P., Sandstrom S.K., Murphy R.F., et al. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res 1998, 4:635-642.
153. Sutton L.M., Warmuth Ma, Petros W.P., Winer E.P. Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. Cancer Chemother Pharmacol 1997, 40:335-341.
154. Widschwendter M., Berger J., Daxenbichler G., Muller-Holzner E., Widschwendter A., Mayr A., et al. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res 1997, 57:4158-4161.
155. Mehrotra J., Vali M., McVeigh M., Kominsky S.L., Fackler M.J., Lahti-Domenici J., et al. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res 2004, 10:3104-3109.
156. Sirchia S.M., Ferguson A.T., Sironi E., Subramanyan S., Orlandi R., Sukumar S., et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 2000, 19:1556-1563.
157. Sirchia S.M., Ren M., Pili R., Sironi E., Somenzi G., Ghidoni R., et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 2002, 62:2455-2461.
158. Qian D.Z., Ren M., Wei Y., Wang X., van de Geijn F., Rasmussen C., et al. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. Prostate 2005, 64:20-28.
159. Pili R., Salumbides B., Zhao M., Altiok S., Qian D., Zwiebel J., et al. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 2012, 106:77-84.
160. Raffoux E., Cras A., Recher C., Boelle P.Y., de Labarthe A., Turlure P., et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010, 1:34-42.
161. Nguyen N., Korangath P., Sabnis G., Brodie A., Ordentlich P., Sterns V., et al. A combination of HDAC inhibitor Entinostat (MS-275), All-Trans-Retinoic Acid (ATRA) and low-dose Doxorubicin causes regression of established xenografts of Triple Negative Breast Cancer [Abstract]. Proceedings of the 101st Annual Meeting at American Association for Cancer Research 2010.
162. Bug G., Ritter M., Wassmann B., et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005, 104:2717-2725.
163. Craddock C., Bradbury C., Narayanan S., et al. Predictors of clinical response in patients with high-risk acute myeloid leukemia receiving treatment with the histone deacetylase inhibitor sodium valproate. ASH Annu Meet Abstr 2005, 106:2791.
164. Kuendgen A., Schmid M., Schlenk R., et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106:112-119.
165. Soriano A.O., Yang H., Faderl S., et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110:2302-2308.
166. Zhang B., Strauss A.C., Chu S., Li M., Ho Y., Shiang K.D., et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010, 17(5):427-442.
167. Korkaya H., Paulson A., Charafe-Jauffret E., Ginestier C., Brown M., Dutcher J., et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 2009, 7(6):e1000121.
168. Kakarala M., Brenner D.E., Korkaya H., Cheng C., Tazi K., Ginestier C., et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 2010, 122(3):777-785.
169. Li Y., Zhang T., Korkaya H., Liu S., Lee H.F., Newman B., et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res 2010, 16(9):2580-2590.
170. Cioce M., Gherardi S., Viglietto G., Strano S., Blandino G., Muti P., et al. Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle 2010, 9(14):2878-2887.
171. Kanwar S.S., Yu Y., Nautiyal J., Patel B.B., Padhye S., Sarkar F.H., et al. Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 2011, 28(4):827-838.
172. Lee T.K., Castilho A., Cheung V.C., Tang K.H., Ma S., Ng I.O. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 2011, 53(1):160-170.
173. Dierks C., Beigi R., Guo G.-R., Zirlik K., Stegert M.R., Manley P., et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14:238-249.
174. Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
175. Dierks C., Beigi R., Guo G.R., Zirlik K., Stegert M.R., Manley P., et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14(3):238-249.
176. Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458(7239):776-779.
177. Sims-Mourtada J., Izzo J.G., Ajani J., Chao K.S. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 2007, 26(38):5674-5679.
178. Mueller M.T., Hermann P.C., Witthauer J., Rubio-Viqueira B., Leicht S.F., Huber S., et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009, 137(3):1102-1113.
179. + leukemic cells. Cancer Sci 2009, 100(5):948-955.
180. Feldmann G., Dhara S., Fendrich V., Bedja D., Beaty R., Mullendore M., et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007, 67(5):2187-2196.